MCKHIGH SIGNALFINANCIAL10-K

McKesson reported extraordinary 297% revenue growth from $28.2B to $112.1B, likely driven by major acquisitions or accounting changes, while maintaining strong operational metrics across cash flow and profitability.

The massive revenue increase far exceeds organic growth possibilities and suggests significant M&A activity, business combinations, or accounting methodology changes that fundamentally altered McKesson's scale and operations. Despite this dramatic expansion, the company maintained operational discipline with operating margins compressing only modestly and generating strong cash flow growth of 41%.

Comparing 2025-05-09 vs 2024-05-08View on EDGAR →
FINANCIAL ANALYSIS

McKesson delivered exceptional financial performance with revenue nearly quadrupling to $112.1B while operating income grew a solid 13% to $4.4B, indicating some margin compression from the revenue expansion. The company strengthened its financial position with operating cash flow surging 41% to $6.1B and cash reserves increasing 24% to $5.7B, while total assets grew 11% to $75.1B. The proportional increases in current assets (+15.5%) and liabilities (+17.7%) suggest the massive revenue growth was supported by expanded working capital needs, but the strong cash generation and balance sheet growth indicate successful integration of whatever drove the revenue surge.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+296.8%
$28.2B$112.1B

Strong top-line growth of 296.8% — accelerating demand or successful expansion into new markets.

Operating Cash Flow
Cash Flow
+41.1%
$4.3B$6.1B

Operating cash flow surged 41.1% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
+35.2%
$71.0M$96.0M

R&D investment increased 35.2% — signals commitment to future product development, though near-term margin impact.

Dividends Paid
Cash Flow
+30.5%
$131.0M$171.0M

Dividend payments increased 30.5% — management confidence in sustained cash generation.

Capital Expenditure
Cash Flow
+24.6%
$431.0M$537.0M

Capex increased 24.6% — ongoing investment in capacity or infrastructure for future growth.

Cash & Equivalents
Balance Sheet
+24.2%
$4.6B$5.7B

Cash grew 24.2% — improving liquidity position supports investment and shareholder returns.

Current Liabilities
Balance Sheet
+17.7%
$52.4B$61.6B

Current liabilities rose 17.7% — increased short-term obligations, watch current ratio.

Current Assets
Balance Sheet
+15.5%
$48.0B$55.4B

Current assets grew 15.5% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
+13.1%
$3.9B$4.4B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Assets
Balance Sheet
+11.4%
$67.4B$75.1B

Asset base grew 11.4% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-05-09
PRIOR — 2024-05-08
ADDED
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 124 9A.
Our RxTS segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies.
RxTS offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, and dispensing support services, in addition to third-party logistics and wholesale distribution support designed to benefit stakeholders.
During fiscal 2025, we completed the sale of Rexall and Well.ca businesses in Canada.
Refer to Financial Note 2, Business Acquisitions and Divestitures, , to the consolidated financial statements included in this Annual Report for more information.
+7 more — sign up free →
REMOVED
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 126 9A.
Our Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma.
RxTS also offers prescription price transparency, benefit insight, dispensing support services, as well as third-party logistics and wholesale distribution support designed to benefit stakeholders.
Health Mart provides franchisees support for operational excellence, managed care contracting, marketing, merchandising solutions, and clinical programs to enhance patient care.
Health Mart Atlas Comprehensive managed care services that help community pharmacies save time, access competitive reimbursement rates, and improve cash flow.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →